Stephens Lowers Lifecore Biomedical (NASDAQ:LFCR) to Equal Weight
Stephens Lowers Lifecore Biomedical (NASDAQ:LFCR) to Equal Weight
Stephens downgraded shares of Lifecore Biomedical (NASDAQ:LFCR – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Monday, The Fly reports.
Separately, Barrington Research reduced their price target on shares of Lifecore Biomedical from $12.00 to $10.00 in a research report on Wednesday, January 11th.
Get Lifecore Biomedical alerts:Lifecore Biomedical Trading Down 6.6 %
Shares of NASDAQ:LFCR opened at $3.04 on Monday. Lifecore Biomedical has a fifty-two week low of $1.52 and a fifty-two week high of $11.95. The stock has a 50-day simple moving average of $5.80. The stock has a market cap of $92.17 million, a price-to-earnings ratio of -1.22 and a beta of 1.11.
About Lifecore Biomedical
(Get Rating)
Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.
Read More
- Get a free copy of the StockNews.com research report on Lifecore Biomedical (LFCR)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
Stephens downgraded shares of Lifecore Biomedical (NASDAQ:LFCR – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Monday, The Fly reports.
斯蒂芬斯降級了 生物醫學生物醫學 (NASDAQ: LFCR — 獲得評級) 《飛翔》報告指出,從周一發給投資者的研究報告中的超重評級到同等體重評級。
Separately, Barrington Research reduced their price target on shares of Lifecore Biomedical from $12.00 to $10.00 in a research report on Wednesday, January 11th.
另外, 巴林頓研究降低了他們的價格目標生物醫學的股票從 $12.00 至 $10.00 在週三的研究報告, 1 月 11 日.
Lifecore Biomedical Trading Down 6.6 %
生醫生物醫學交易下降 6.6%
Shares of NASDAQ:LFCR opened at $3.04 on Monday. Lifecore Biomedical has a fifty-two week low of $1.52 and a fifty-two week high of $11.95. The stock has a 50-day simple moving average of $5.80. The stock has a market cap of $92.17 million, a price-to-earnings ratio of -1.22 and a beta of 1.11.
納斯達克:LFCR 的股票在周一 3.04 美元開盤。生物醫學有五十二周低點 1.52 美元和五十二周高點 11.95 美元。該股票的 50 天簡單移動平均線為 5.80 美元。該股的市值為 92.17 萬美元,價格與收益比為 -1.22,測試版為 1.11。
About Lifecore Biomedical
關於生命醫學
(Get Rating)
(取得評分)
Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.
Lifeore 生物醫藥有限公司從事食品和生物材料市場的健康和保健產品的設計,開發,製造和銷售。它通過以下部分進行操作:生活,策劃食品和其他。Lifecore 部門銷售使用玻尿酸的產品,玻尿酸是一種天然存在的多醣體,廣泛分佈在動物和人類結締組織的細胞外基質中。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Lifecore Biomedical (LFCR)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
- 獲取有關生醫藥研究報告的免費副本
- KB 首頁強勁業績提升價格
- 耐嚼的股票正在建立長期盈利增長
- 為什麼華爾街喜歡這 3 竹篙股票
- 低容量邦吉暴跌提出了機會
- 卡瓦納今年可能能夠達到盈利能力
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
接收生命科生物醫學日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Lifeore 生物醫學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧